Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/17/2017 02/20/2017 02/21/2017 02/22/2017 02/23/2017 Date
4.85(c) 4.82(c) 4.875(c) 4.875(c) 4.645(c) Last
156 000 26 265 93 734 271 470 368 154 Volume
-0.51% -0.62% +1.14% 0.00% -4.72% Change
More quotes
Financials ( GBP)
Sales 2016 2,70 M
EBIT 2016 -2,70 M
Net income 2016 -2,40 M
Debt 2016 5,60 M
Yield 2016 -
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -1,40 M
Debt 2017 7,40 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 7,14x
EV / Sales2017 5,14x
Capitalization 13,7 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
02/09 PROTEOME SCIENCES : Trading Update and Notice of Results
02/09 PROTEOME SCIENCES : Expects Narrowed Loss, Appoints Commercial Officer
01/05 PROTEOME SCIENCES : Holdings in Company and PDMR Shareholding
01/03 DIRECTOR DEALINGS SUMMARY : Proteome Sciences Non-Executive Lifts Stake
01/03 DIRECTOR DEALINGS : Vehicle of Proteome Non-Executive Buys Shares
2016 PROTEOME SCIENCES : Result of General Meeting and Completion of Placing
2016 PROTEOME SCIENCES : Placing and Subscription of 66,258,100 new Ordinary Shares &..
2016 PROTEOME SCIENCES : Raises GBP3.3 Million In Discounted Placing (ALLISS)
2016 PROTEOME SCIENCES : Spectrometry Technique Dramatically Enhances Detection of Ke..
2016 PROTEOME SCIENCES : Stacking the odds in Alzheimer's Disease Drug Development #W..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
Latest Tweets
08:36aProteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
02/09Proteome Sciences : Trading Update and Notice of Results  
02/09Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
2016Proteome Sciences plc $PRM Insider Roger Steven McDowell Purchases 2,000,000 .. 
2016Proteome Sciences : Placing and Subscription of 66,258,100 new Ordinary Share.. 
More tweets
Qtime:4
Advertisement
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Full-screen chart
Technical analysis trends PROTEOME SCIENCES...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts 0
Average target price 0,12  GBP
Spread / Average Target 158%
Consensus details
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Executive Chairman
Ian H. Pike Chief Operating Officer & Executive Director
Geoffrey John Ellis Secretary, Executive & Finance Director
Malcolm Ward Chief Technical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-15.55%17
AMGEN, INC.18.06%128 150
CELGENE CORPORATION3.04%92 936
GILEAD SCIENCES, INC.-3.13%91 392
REGENERON PHARMACEUTIC..0.85%38 291
ACTELION LTD22.45%28 790
More Results